Last updated: September 8, 2026
KRYSTEXXA, or pegloticase, is Amgen’s specialty biologic for adults with chronic gout refractory to conventional therapy. The product has developed into a billion-dollar franchise through high treatment value, limited direct competition, repeat infusion demand, and expanded use with methotrexate. Its main commercial risks are infusion-center capacity, high payer scrutiny, treatment discontinuation, and eventual biosimilar competition.
KRYSTEXXA revenue increased from approximately $370 million in 2020 to more than $1 billion after Amgen acquired Horizon Therapeutics. The product remains protected by biologic regulatory complexity and manufacturing barriers, although its original 12-year U.S. biologic exclusivity period has expired.
What is KRYSTEXXA and how does it work?
KRYSTEXXA is an intravenous recombinant uricase enzyme. Its active ingredient, pegloticase, converts uric acid into allantoin, a more soluble metabolite that can be eliminated through the kidneys.
The FDA approved KRYSTEXXA in September 2010 under Biologics License Application No. 125293. The approved indication is chronic gout in adults refractory to conventional therapy, also described as uncontrolled gout that has not responded adequately to, or cannot tolerate, conventional treatment.[1]
The standard regimen is an 8 mg intravenous infusion every two weeks. The label contains a boxed warning for anaphylaxis and infusion reactions. Patients must be screened for glucose-6-phosphate dehydrogenase deficiency because pegloticase can cause hemolysis and methemoglobinemia in affected individuals.[1]
What changed with methotrexate co-therapy?
In 2022, the FDA approved labeling for KRYSTEXXA administered with methotrexate. The MIRROR randomized clinical program showed that methotrexate co-therapy improved sustained urate-lowering response and reduced treatment discontinuation compared with KRYSTEXXA alone.[2]
The commercial importance of this label expansion is substantial:
| Commercial effect |
Impact on KRYSTEXXA |
| Higher response persistence |
Supports longer treatment duration |
| Lower immunogenicity |
May reduce anti-drug antibody formation |
| Fewer infusion interruptions |
Improves revenue per treated patient |
| Broader rheumatology adoption |
Reduces concern about monotherapy failure |
| More complex treatment protocol |
Adds monitoring and methotrexate-management requirements |
Methotrexate does not replace KRYSTEXXA. It is an adjunct intended to improve the biologic’s durability and treatment success.
How large is the KRYSTEXXA market?
KRYSTEXXA targets a narrow but commercially valuable segment of the gout market. Most gout patients receive oral urate-lowering therapy, including generic allopurinol or febuxostat. KRYSTEXXA is reserved for patients with severe, chronic, uncontrolled disease and substantial urate burden.
The commercial model depends on four factors:
- Identification of refractory patients.
- Referral to rheumatologists experienced with intravenous biologics.
- Access to infusion facilities and payer authorization.
- Sustained treatment after the initial response period.
The eligible population is much smaller than the overall gout population, but treatment value per patient is high. The product also addresses a group with limited effective alternatives. Oral therapies remain the primary competitive constraint, while no other FDA-approved uricase biologic directly competes with pegloticase in the United States.
Which products compete with KRYSTEXXA?
| Product or class |
Status |
Relationship to KRYSTEXXA |
| Allopurinol |
Generic oral therapy |
First-line standard treatment |
| Febuxostat |
Generic oral therapy |
Alternative xanthine oxidase inhibitor |
| Probenecid |
Generic uricosuric |
Used in selected patients |
| Lesinurad |
Withdrawn from U.S. market |
No longer a meaningful U.S. competitor |
| Pegadricase and other uricases |
Investigational or non-U.S. depending on product |
Potential future biologic competition |
| KRYSTEXXA |
FDA-approved IV biologic |
Treats refractory chronic gout |
KRYSTEXXA competes less on prescription volume than on treatment escalation. Its market expands when physicians identify patients who have failed multiple oral regimens, when infusion access improves, and when the methotrexate label increases confidence in sustained response.
What is the financial trajectory of KRYSTEXXA?
KRYSTEXXA produced rapid revenue growth before and after Horizon’s acquisition. The following figures reflect reported product sales in company filings and are rounded where appropriate.
| Year |
Reported KRYSTEXXA revenue |
Year-over-year trend |
Commercial context |
| 2020 |
Approximately $370 million |
Strong growth |
Horizon expanded specialist adoption |
| 2021 |
Approximately $565 million |
Approximately 53% |
Greater diagnosis and treatment penetration |
| 2022 |
Approximately $876 million |
Approximately 55% |
Methotrexate label expansion and continued demand |
| 2023 |
More than $1.0 billion |
Continued growth |
Full-year Amgen ownership after Horizon acquisition |
| 2024 |
Approximately $1.1 billion or more |
Moderate growth |
Mature blockbuster scaling under Amgen |
Horizon reported KRYSTEXXA net sales of $875.6 million in 2022, compared with $565.4 million in 2021 and $370.4 million in 2020.[3] Amgen acquired Horizon in October 2023 for approximately $27.8 billion, making KRYSTEXXA one of the central assets supporting the transaction.[4]
The financial trajectory indicates a transition from high-growth specialty product to mature biologic franchise. Growth is likely to depend more on treated-patient expansion, persistence, and international commercialization than on large price increases.
What drives KRYSTEXXA revenue?
The strongest revenue drivers are:
- Increased diagnosis of uncontrolled gout.
- More aggressive referral of refractory patients.
- Methotrexate-supported treatment persistence.
- Greater use in patients with visible tophi and high disease burden.
- Expansion of infusion capacity.
- Improved payer coverage and prior-authorization execution.
- Continued physician familiarity with the product.
The main revenue constraint is treatment attrition. Patients can discontinue because of infusion reactions, loss of response, immunogenicity, cost-sharing, comorbidities, or difficulty maintaining biweekly appointments.
When does KRYSTEXXA lose exclusivity?
KRYSTEXXA’s principal U.S. biologic regulatory exclusivity period began with its 2010 approval. Under the Biologics Price Competition and Innovation Act, reference biologics generally receive 12 years of FDA data exclusivity. That period therefore expired in 2022 for KRYSTEXXA, subject to the statutory treatment of the specific application and any applicable pediatric extension.[5]
Expiration of regulatory exclusivity does not create automatic generic entry. KRYSTEXXA is a biologic, so follow-on competition would proceed through the abbreviated biosimilar pathway under Section 351(k) of the Public Health Service Act rather than the conventional ANDA pathway.
What is the Orange Book status of KRYSTEXXA?
KRYSTEXXA is not regulated as a conventional small-molecule drug and is not expected to have an Orange Book patent-listing profile comparable to products such as Humira, Eliquis, or Januvia. Biologics are generally tracked through the FDA’s Purple Book and the biologics licensing framework.
A prospective competitor would need to address:
- Biosimilar analytical comparability.
- Clinical or pharmacodynamic evidence required by FDA.
- Immunogenicity risk.
- Complex manufacturing and purification.
- Interchangeability requirements if the applicant seeks interchangeable status.
- Patent litigation under the BPCIA.
There is no Paragraph IV challenge in the traditional Hatch-Waxman sense for KRYSTEXXA. Biosimilar applicants use the BPCIA patent-information exchange and litigation framework, often called the patent dance, rather than filing an ANDA Paragraph IV certification.
What patents and manufacturing protections cover KRYSTEXXA?
KRYSTEXXA’s practical protection is broader than one composition-of-matter patent. The relevant protection may include:
- Pegloticase composition and sequence claims.
- PEGylation and protein-conjugation technology.
- Formulation and stability claims.
- Dosing and administration claims.
- Combination use with methotrexate.
- Manufacturing, purification, and process-control methods.
- Device, packaging, and infusion-related claims.
The most material barrier is manufacturing complexity. Pegloticase is a PEGylated enzyme that requires control of protein structure, PEG conjugation, aggregation, impurities, potency, and immunogenicity. A biosimilar developer must demonstrate high similarity across these attributes while establishing a reliable commercial process.
Are KRYSTEXXA formulation patents important?
Formulation and manufacturing patents can extend competitive protection after the expiry of core biologic exclusivity. Their value depends on claim scope, validity, enforceability, prosecution history, and whether a biosimilar can design around the claims.
The 2022 methotrexate label expansion is commercially important but does not automatically create a broad method-of-use barrier. A biosimilar applicant may seek a restricted label that omits protected indications or dosing instructions, depending on the patent landscape and FDA requirements.
Because KRYSTEXXA is an infused biologic, the commercial impact of process patents may be greater than for a simple oral tablet. A competitor cannot rely only on a chemically similar active ingredient. It must reproduce a complex biological product at commercial scale.
What is the biosimilar risk for KRYSTEXXA?
As of the latest public company and FDA materials through 2024, KRYSTEXXA had no FDA-approved biosimilar competitor. The absence of a biosimilar does not eliminate future risk, but it indicates that the product’s remaining protection is supported by development cost, manufacturing complexity, clinical risk, and the limited size of the target market.
Biosimilar entry barriers
| Barrier |
Effect on competitors |
| Complex PEGylated enzyme |
Raises analytical-development burden |
| Immunogenicity |
Increases clinical and regulatory risk |
| Intravenous administration |
Requires infusion-center adoption |
| Narrow patient population |
Limits expected return on development investment |
| High manufacturing cost |
Reduces price-cutting flexibility |
| Specialist prescribing |
Slows substitution |
| Methotrexate co-therapy |
Creates a differentiated treatment protocol |
The first biosimilar could face a market with attractive price potential but limited unit volume. A 20% to 40% discount could expand access while still preserving a meaningful commercial opportunity, but actual uptake would depend on interchangeability, payer contracts, physician confidence, and infusion-provider economics.
What patent litigation and settlement risks affect KRYSTEXXA?
No major public U.S. Paragraph IV litigation profile comparable to leading small-molecule blockbusters has defined KRYSTEXXA. That is consistent with its biologic status.
Future litigation could arise from:
- BPCIA patent exchanges with biosimilar developers.
- Claims covering pegylated uricase compositions.
- Process and purification patents.
- Formulation and stability patents.
- Method-of-use claims involving methotrexate co-therapy.
- Patent-term or regulatory exclusivity disputes.
A settlement could delay biosimilar launch while preserving a negotiated entry date. The commercial value of such a settlement would depend on the remaining enforceable patent term, the number of potential entrants, and whether the settlement includes supply, licensing, or authorized-biosimilar provisions.
How does Amgen ownership change KRYSTEXXA’s outlook?
Amgen provides KRYSTEXXA with a larger commercial infrastructure, specialty-market expertise, manufacturing resources, and global regulatory capabilities. The acquisition also places the product alongside Amgen’s broader inflammation and immunology portfolio.
The principal benefits are:
- Greater sales-force reach.
- Stronger payer and distribution capabilities.
- More capacity for lifecycle management.
- Better integration with specialty pharmacy and infusion channels.
- Ability to fund post-approval studies and additional commercial initiatives.
The principal financial issue is acquisition economics. Amgen paid a substantial premium for Horizon, so KRYSTEXXA growth must support the transaction alongside Horizon’s other assets. A mature product with annual sales above $1 billion can support significant cash generation, but growth deceleration increases pressure on pricing, operating efficiency, and lifecycle management.
What generic launch scenarios exist for KRYSTEXXA?
Scenario 1: No biosimilar before 2028
KRYSTEXXA remains the sole approved U.S. uricase biologic. Revenue grows at a low single-digit rate through patient expansion and improved persistence.
Scenario 2: One biosimilar entrant
The first entrant targets high-volume rheumatology accounts and payer contracts. Net pricing declines, but Amgen retains substantial share because of brand familiarity, clinical experience, and physician preference.
Scenario 3: Multiple biosimilars
Competition shifts from clinical differentiation to contracting and supply reliability. Price erosion becomes more pronounced, particularly in institutional channels and large payer networks.
Scenario 4: New urate-lowering biologic
A next-generation uricase or alternative enzyme could exert greater pressure than a standard biosimilar if it offers less frequent dosing, lower immunogenicity, or easier administration.
How strong is the KRYSTEXXA patent estate?
KRYSTEXXA has a commercially meaningful protection profile, but its strength is based on multiple layers rather than unexpired core exclusivity alone.
| Protection layer |
Current strategic value |
| 2010 biologic approval |
Regulatory history and physician familiarity |
| 12-year biologic exclusivity |
Expired in the United States |
| Composition and protein claims |
Potentially relevant against biosimilar products |
| Formulation claims |
May constrain product design |
| Manufacturing claims |
Important because of complex PEGylation |
| Methotrexate use claims |
Supports lifecycle differentiation |
| Brand and infusion infrastructure |
Significant non-patent protection |
The strongest commercial moat is likely the combination of clinical data, manufacturing know-how, infusion logistics, and provider familiarity. Patent strength must be assessed claim by claim; regulatory exclusivity alone no longer blocks U.S. biosimilar development.
What is the FDA regulatory status of KRYSTEXXA?
KRYSTEXXA is FDA-approved for refractory chronic gout in adults. Its key regulatory characteristics are:
| Item |
Status |
| Active ingredient |
Pegloticase |
| Dosage form |
Intravenous infusion |
| Initial FDA approval |
September 2010 |
| Application |
BLA 125293 |
| Primary use |
Chronic gout refractory to conventional therapy |
| Label expansion |
Methotrexate co-therapy approved in 2022 |
| Regulatory pathway for competitors |
351(k) biosimilar pathway |
| Orange Book listing |
Not the primary biologic patent framework |
| Purple Book relevance |
Yes |
| FDA-approved biosimilar identified through 2024 |
None publicly identified |
Key Takeaways
- KRYSTEXXA is a high-value specialty biologic for refractory chronic gout.
- Revenue rose from about $370 million in 2020 to more than $1 billion after the Horizon acquisition.
- Methotrexate co-therapy improved the product’s clinical and commercial profile by supporting response persistence.
- U.S. biologic data exclusivity expired in 2022, but no FDA-approved biosimilar had entered the market through 2024.
- KRYSTEXXA does not have a conventional Paragraph IV or Orange Book litigation profile.
- Manufacturing complexity, immunogenicity risk, infusion delivery, and a narrow patient population delay and complicate biosimilar competition.
- Amgen ownership strengthens commercialization and lifecycle-management capabilities.
- Long-term revenue risk depends primarily on biosimilar timing, treatment persistence, payer pressure, and the emergence of a lower-burden urate-lowering biologic.
FAQs
Does KRYSTEXXA have an FDA-approved generic?
No. KRYSTEXXA is a biologic, so competition would enter through the FDA’s biosimilar pathway rather than as a conventional generic tablet.
Is KRYSTEXXA covered by Medicare?
Coverage depends on the patient’s Medicare benefit, diagnosis, site of infusion, supplemental coverage, and payer authorization. Reimbursement can differ materially between physician-office and hospital outpatient settings.
Can KRYSTEXXA be administered without methotrexate?
Yes. Methotrexate co-therapy is recommended for eligible patients because it can improve response persistence, but treatment decisions depend on contraindications, comorbidities, and physician judgment.
Why is KRYSTEXXA expensive compared with allopurinol?
KRYSTEXXA is a complex recombinant enzyme administered by intravenous infusion to a narrowly defined refractory population. Allopurinol is a low-cost oral generic used broadly as first-line therapy.
Could a new uricase replace KRYSTEXXA?
A competitor could displace KRYSTEXXA if it provides lower immunogenicity, less frequent dosing, simpler administration, or stronger sustained-response data. No such product had established FDA approval in the United States through 2024.
References
-
U.S. Food and Drug Administration. (2024). Krystexxa (pegloticase) prescribing information. FDA.
-
Botson, J. K., et al. (2023). Methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: The MIRROR randomized clinical trial. Arthritis & Rheumatology.
-
Horizon Therapeutics plc. (2023). Annual report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
Amgen Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
